Passage Bio, Inc. Stock Price, News & Analysis

Passage Bio (Nasdaq: PASG) expanded its collaboration with the University of Pennsylvania’s Gene Therapy Program to enhance genetic medicines for CNS disorders, focusing on Alzheimer's Disease and Temporal Lobe Epilepsy. The company expects to initiate Phase 1/2 trials for PBFT02 and PBKR03 by Q3 2021 and report initial safety data from PBGM01 in Q4 2021. Financially, Passage Bio reported a net loss of $48.4 million for Q2 2021, an increase from $27.2 million in Q2 2020, while cash reserves grew to $407.8 million, ensuring operational funding for at least 24 months.

Passage Bio (Nasdaq: PASG) expresses deep sorrow over the unexpected passing of founder and chairman, Dr. Tadataka Yamada, on August 3, 2021. Dr. Yamada contributed significantly to the company and the life sciences industry, serving as chairman since July 2017 and previously holding prestigious roles at Takeda and GlaxoSmithKline. His strategic insight shaped the company’s development of transformative genetic therapies for CNS disorders. Passage Bio aims to continue his legacy while maintaining a commitment to patients and innovation in gene therapy.

Passage Bio, Inc. (NASDAQ: PASG) announced that CEO Bruce Goldsmith will participate in a virtual panel at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference, scheduled for August 10-12, 2021. Goldsmith's participation is set for August 11 at 8:35 a.m. ET. The event will be accessible via live webcast on the company's website, with a replay available for 30 days post-event. Passage Bio is dedicated to developing gene therapies for rare central nervous system disorders and has a collaboration with the University of Pennsylvania’s Gene Therapy Program.

Passage Bio (NASDAQ: PASG) will host a conference call on August 5, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and recent business highlights. Investors can join the call by dialing 833-528-0605 (domestic) or 830-221-9711 (international), using conference ID 4037236. The call will also be available as a live audio webcast on the company’s website, with an archived version accessible for 30 days post-event. Passage Bio focuses on gene therapies for rare CNS disorders and collaborates with the University of Pennsylvania for its research.

Passage Bio, a clinical-stage genetic medicines company, granted an inducement award to its new Chief Commercial Officer, M. Maria Törnsén. This includes options to buy 200,000 shares at $13.04 each and 20,000 restricted stock units, vesting over four years. The award aligns with Nasdaq Rule 5635(c)(4) and aims to attract talent to advance therapies for rare CNS disorders. Passage Bio is focused on innovative gene therapies in partnership with the University of Pennsylvania's Gene Therapy Program to enhance its pipeline.

Passage Bio, Inc. (Nasdaq: PASG) has announced key leadership appointments, enhancing its capability in developing transformative therapies for rare CNS disorders. Effective immediately, Maria Törnsén takes on the role of Chief Commercial Officer, while Simona King will join as Chief Financial Officer on August 23, and Mark Forman, M.D., Ph.D. will assume the role of Chief Medical Officer on July 30. These appointments aim to bolster Passage Bio's pipeline and drive growth, positioning the company well for future clinical developments in gene therapy for patients in need.

Passage Bio (Nasdaq: PASG) announced the election of Dr. Derrell D. Porter to its Board of Directors and Audit Committee, effective May 27, 2021. Dr. Porter brings extensive experience in corporate strategy and product development from his leadership roles at Cellevolve Bio and Atara Biotherapeutics. His addition is expected to enhance the company's strategic direction in developing therapies for rare CNS disorders. Dr. Porter replaces Patrick Heron, who did not stand for re-election. The board aims to leverage Dr. Porter's expertise to strengthen commercial strategies for their gene therapies.

Passage Bio (NASDAQ: PASG) announced its participation in two virtual investor conferences in June 2021. The Jefferies Healthcare Conference will take place on June 2 at 4:30 p.m. ET, featuring a presentation format. On June 10, Passage Bio will engage in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference at 11:20 a.m. ET. Both events will be available via live webcast on the company's website, with replays accessible for 30 days post-event. As a clinical-stage genetic medicines firm, Passage Bio focuses on innovative therapies for rare CNS disorders.

Passage Bio (Nasdaq: PASG) announced a significant presentation by the University of Pennsylvania’s Gene Therapy Program at the ASGCT annual meeting, showcasing a new mouse model to evaluate gene therapy efficacy for metachromatic leukodystrophy (MLD). Preliminary results indicate that Passage Bio’s candidate PBML04 showed promising efficacy, reducing neurological deficits in this model. This advancement addresses the challenge of limited mouse models for MLD, facilitating the preclinical evaluation of AAV-mediated gene therapy. The company aims to advance its IND-enabling studies for PBML04.